Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19

Summary

Background. Angiotensing converting enzyme type 2 (ACE2), a key enzyme of the renin-angiotensin-aldosterone system (RAAS), is the receptor of SARS-CoV-2 for cell entry into lungs. Because ACE2 may be modulated by RAAS inhibitors, such as angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEi and ARBs may be at higher risk for COVID-19 infection and severity.

Aim. To analyze the associations between COVID-19 and hypertension, and treatments with ACEi and ARBs.

Methods. In this retrospective observational study, consecutive patients hospitalized for suspected COVID-19 pneumonia will be divided into 2 groups, whether or not COVID-19 is confirmed. The two groups will be compared for baseline characteristics, mainly prior treatment with ACEi and ARBs, and clinical outcome at 1-month follow-up.

The main hypothesis is that ACEi and ARBs, which interact differently with ACE2, may have different relationships with COVID-19 infection or severity.

Conditions

• COVID-19

Sponsors & Collaborators

• Bernard LIVAREK, MD, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Jean-Paul BERESSI, MD, Department of diabetology, Versailles Hospital

  collaborator UNKNOWN

• Mehrsa KOUKABI FRADELIZZI, MD, Emergency department, Versailles Hospital

  collaborator UNKNOWN

• Floriane GILLES, MD, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Alisson BERTRAND, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Marie DE TOURNEMIRE, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Victorien MONGUILLON, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Maeva PASQUALINI, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Alix PREVOT, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Guillaume ROGER, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Joseph SABA, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Joséphine SOLTANI, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Jean-François PROST, Cardiology department, Versailles Hospital

  collaborator UNKNOWN

• Cécile LAUREANA, Department of medical information, Versailles Hospital

  collaborator UNKNOWN

• Versailles Hospital

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-01

Primary Completion

2020-06-01

Completion

2020-07-01